Novel Multitarget Hybrid Compounds for the Treatment of Alzheimer’s Disease

Author(s): Patrycja Michalska, Izaskun Buendia, Laura del Barrio, Rafael Leon

Journal Name: Current Topics in Medicinal Chemistry

Volume 17 , Issue 9 , 2017

Become EABM
Become Reviewer
Call for Editor


Alzheimer’s disease (AD) is the most prevalent among the aging diseases known as neurodegenerative disorders. Drug design programs over the last two decades were mainly based on the cholinergic, the amyloid or the tau hypothesis. However, none of the new drugs have a real impact on the outcome of the disease. The complex nature of AD has led to new approaches for drug development programs, the multitarget drug design hypothesis. Based on this hypothesis, the generation of multitarget hybrid compounds from previously known active molecules has been one of the most widely used to obtain new candidates for the future treatment of AD. Here, we summarize recent developments based on the hybridization hypothesis to obtain a potential clinical candidate for AD.

Keywords: Alzheimer's disease, Hybrid compounds, Drug design, Multitarget drugs, Emerging targets for AD, Dual AChE Inhibitors, Antioxidants, Nrf2-EpRE inducers.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [1027 - 1043]
Pages: 17
DOI: 10.2174/1568026616666160927154116
Price: $65

Article Metrics

PDF: 53
PRC: 1